Balyasny Asset Management’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

Balyasny Asset Management’s Portfolio PEARW Stock Details PEARW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-145,600	Closed	-$2.77K	–	3192
2023 Q1	$2.77K	Sell	145,600 -4,400	-3%	-$424	﹤0.01%	2565
2022 Q4	$22.3K	Hold	150,000	–	–	﹤0.01%	2470
2022 Q3	$25K	Hold	150,000	–	–	﹤0.01%	2557
2022 Q2	$23K	Hold	150,000	–	–	﹤0.01%	2465
2022 Q1	$119K	Hold	150,000	–	–	﹤0.01%	2116
2021 Q4	$90K	Sell	150,000 -50,000	-25%	-$50.8K	﹤0.01%	1976
2021 Q3	$190K	Hold	200,000	–	–	﹤0.01%	1650
2021 Q2	$280K	Buy	+200,000	New	+$175K	﹤0.01%	1664

Other funds holding PEARW

Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

Balyasny Asset Management's PEARW Position: Q2 2023 in Review

Balyasny Asset Management sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q2 2023, closing a stake of 145,600 shares — an estimated $2.77K sold.

Balyasny Asset Management first reported a position in PEARW in Q2 2021 and held it in 8 quarters. The position peaked at $280K in Q2 2021. 2 funds tracked by Wall St. Rank hold PEARW as of Q2 2023.

Balyasny Asset Management reported no remaining Pear Therapeutics, Inc. Warrant position as of Q2 2023 after selling out during the quarter.
Balyasny Asset Management sold 145,600 Pear Therapeutics, Inc. Warrant shares in Q2 2023, an estimated $2.77K.
Balyasny Asset Management first reported a position in Pear Therapeutics, Inc. Warrant in Q2 2021 and held it in 8 quarters.
Balyasny Asset Management's Pear Therapeutics, Inc. Warrant position peaked at $280K in Q2 2021.
2 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q2 2023.

Based on Balyasny Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.